Egalet Corporation
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | Egalet Corporation |
Stock Symbol : | NASDAQ: EGLT |
Class Period Start: | 12/15/2015 |
Class Period End: | 01/09/2017 |
Lead Plaintiff motion: | 03/28/2017 |
Date Filed: | 01/27/2017 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the Eastern District of Pennsylvania |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the March 28, 2017 lead plaintiff deadline in a class action lawsuit filed against Egalet Corporation (NASDAQ: EGLT) (“Egalet” or “the Company”). The suit is pending in the U.S. District Court for the Eastern District of Pennsylvania and investors, who purchased Egalet Corporation securities between December 15, 2015 and January 9, 2017, have until March 28, 2017 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased Egalet Corporation securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Egalet misrepresented ARYMO ER’s oral abuse-deterrent profile; Egalet falsely or misleadingly overstated ARYMO ER’s chances to receive the oral abuse-deterrent labeling; the Company’s New Drug Application for ARYMO ER lacked sufficient data to support the oral-labeling claims; the label was likely not to include the oral abuse-deterrent claims; and as a result of the foregoing, Egalet’s public statements were materially false and misleading at all relevant times. On January 9, 2017, the Company released a statement announcing the approval of its product Arymo ER. Later, FDA revealed that a competitor product MorphaBond "has marketing exclusivity for labeling describing the expected reduction of abuse of single-entity extended-release morphine by the intranasal route due to physicochemical properties." On this news, NASDAQ: EGLT shares fell harming investors. If you were negatively impacted by your investment in Egalet Corporation securities between December 15, 2015 and January 9, 2017 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |